文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

美国慢性血栓栓塞性肺动脉高压登记研究:入组特征与1年随访结果

Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-up.
PubMed 文献 · Chest · 2021-06-04
一句话结论多中心前瞻性登记显示,可手术的慢性血栓栓塞性肺动脉高压患者接受肺动脉血栓内膜剥脱术后1年WHO功能分级1-2级比例达82.9%,显著优于不可手术组(48.2%)和可手术未手术组(56%)。

美国慢性血栓栓塞性肺动脉高压登记(US-CTEPH-R)为多中心、前瞻性、纵向观察性登记,纳入新诊断(<6个月)CTEPH患者,要求右心导管证实平均肺动脉压≥25 mmHg且影像学确认CTEPH。2015至2018年共纳入750例,随访至2019年,每半年一次。87.9%有急性肺栓塞史,诊断延迟中位10个月,入组时多数为WHO功能分级3级,中位平均肺动脉压44 mmHg。接受PTE手术者中位肺血管阻力从6.9降至2.6 Wood单位(P<.001),院内死亡率3.9%;1年时手术组WHO功能分级1-2级比例82.9%,高于不可手术组48.2%和可手术未手术组56%(P<.001)。

要点

  • CTEPH诊断延迟常见,中位延迟10个月;入组时多数患者WHO功能分级3级,中位平均肺动脉压44 mmHg。
  • PTE手术使中位肺血管阻力从6.9降至2.6 Wood单位(P<.001),院内死亡率为3.9%。
  • 1年随访时,手术组WHO功能分级1-2级比例为82.9%,不可手术组为48.2%,可手术未手术组为56%(P<.001)。
  • 不可手术患者较手术患者年龄更大、较少肥胖、较少有DVT史、非O型血或易栓症,更常有COPD或癌症史。
  • 1年随访时,手术组接受氧疗、利尿剂或肺动脉高压靶向治疗的比例低于不可手术组。

适用人群与场景

  • 新诊断(<6个月)CTEPH患者,右心导管证实平均肺动脉压≥25 mmHg且影像学确认CTEPH。
  • 2015至2018年纳入750例,随访至2019年,每半年随访一次。

诊断标准与关键阈值

  • 入组标准:右心导管证实平均肺动脉压≥25 mmHg,且影像学确认CTEPH。
  • 诊断延迟中位10个月;入组时多数患者WHO功能分级3级,中位平均肺动脉压44 mmHg。

处置流程与药物剂量

  • 可手术患者接受肺动脉血栓内膜剥脱术(PTE),中位肺血管阻力从6.9降至2.6 Wood单位(P<.001)。
  • 1年随访时,手术组接受氧疗、利尿剂或肺动脉高压靶向治疗的比例低于不可手术组。

研究设计与关键结果

  • 多中心、前瞻性、纵向观察性登记,纳入750例新诊断CTEPH患者,分为手术组(n=566)、可手术未手术组(n=88)和不可手术组(n=96)。
  • 87.9%患者有急性肺栓塞史;诊断延迟中位10个月;入组时多数WHO功能分级3级,中位平均肺动脉压44 mmHg。
  • 不可手术患者较手术患者年龄更大、较少肥胖、较少有DVT史、非O型血或易栓症,更常有COPD或癌症史。
  • PTE术后中位肺血管阻力从6.9降至2.6 Wood单位(P<.001),院内死亡率3.9%。
  • 1年随访时,手术组WHO功能分级1-2级比例为82.9%,不可手术组为48.2%,可手术未手术组为56%(P<.001)。
  • 1年随访时,手术组接受氧疗、利尿剂或肺动脉高压靶向治疗的比例低于不可手术组。

证据类型、等级与局限

  • 证据类型:多中心、前瞻性、纵向、观察性登记研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于新诊断CTEPH患者,应评估手术可操作性;接受PTE手术的患者1年WHO功能分级1-2级比例更高(82.9% vs 不可手术组48.2% vs 可手术未手术组56%,P<.001)。
  • PTE手术可使中位肺血管阻力从6.9降至2.6 Wood单位(P<.001),院内死亡率为3.9%。
  • 1年随访时,手术组接受氧疗、利尿剂或肺动脉高压靶向治疗的比例低于不可手术组。

指南或共识出处

  • 美国慢性血栓栓塞性肺动脉高压登记(US-CTEPH-R),ClinicalTrials.gov注册号NCT02429284。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The United States Chronic Thromboembolic Pulmonary Hypertension Registry (US-CTEPH-R) was designed to characterize the demographic characteristics, evaluation, clinical course, and outcomes of surgical and nonsurgical therapies for patients with chronic thromboembolic pulmonary hypertension.

RESEARCH QUESTION: What are the differences in baseline characteristics and 1-year outcomes between operated and nonoperated subjects?

STUDY DESIGN AND METHODS: This study describes a multicenter, prospective, longitudinal, observational registry of patients newly diagnosed (< 6 months) with CTEPH. Inclusion criteria required a mean pulmonary artery pressure ≥ 25 mm Hg documented by right heart catheterization and radiologic confirmation of CTEPH. Between 2015 and 2018, a total of 750 patients were enrolled and followed up biannually until 2019.

RESULTS: Most patients with CTEPH (87.9%) reported a history of acute pulmonary embolism. CTEPH diagnosis delays were frequent (median, 10 months), and most patients reported World Health Organization functional class 3 status at enrollment with a median mean pulmonary artery pressure of 44 mm Hg. The registry cohort was subdivided into Operable patients undergoing pulmonary thromboendarterectomy (PTE) surgery (n = 566), Operable patients who did not undergo surgery (n = 88), and those who were Inoperable (n = 96). Inoperable patients were older than Operated patients; less likely to be obese; have a DVT history, non-type O blood group, or thrombophilia; and more likely to have COPD or a history of cancer. PTE resulted in a median pulmonary vascular resistance decline from 6.9 to 2.6 Wood units (P < .001) with a 3.9% in-hospital mortality. At 1-year follow-up, Operated patients were less likely treated with oxygen, diuretics, or pulmonary hypertension-targeted therapy compared with Inoperable patients. A larger percentage of Operated patients were World Health Organization functional class 1 or 2 at 1 year (82.9%) compared with the Inoperable (48.2%) and Operable/No Surgery (56%) groups (P < .001).

INTERPRETATION: Differences exist in the clinical characteristics between patients who exhibited operable CTEPH and those who were inoperable, with the most favorable 1-year outcomes in those who underwent PTE surgery.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02429284; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Kerr KM, Elliott CG, Chin K, et al. Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-up. Chest. 2021. PMID: 34090871. doi:10.1016/j.chest.2021.05.052

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。